Drug · Other

Triptorelin

CI-DRUG-00000702Explore in graph →CHEMBL1201334 Approved

Regulatory

Approvals (8)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory8 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as TRELSTAR (DIN 02412322) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Oct 16, 2013	health-canada-dpd
CA Health Canada	—	Marketed in Canada as DECAPEPTYL (DIN 02389282) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 9, 2012	health-canada-dpd
CA Health Canada	—	Marketed in Canada as TRELSTAR (DIN 02243856) under ATC L02AE04 TRIPTORELIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 15, 2005	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 15 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	13	9	22	58	8	CA, US	Jun 15, 2000	1997-04
Malignant Prostate Neoplasm	Approved	Phase 4	9	6	13	31	3	US	Jun 15, 2000	1997-04
Malignant Breast Neoplasm	Phase3	Phase 3	1	1	6	12	0	—	—	2003-08
Hodgkin Lymphoma	Phase Not Stated	N/A	0	0	0	1	0	—

Curated evidence

Clinical evidence (0)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

Data not yet available

No curated evidence item mentions this therapy yet.

Clinical trials

Trials with this intervention (63)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 51–63 of 63 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00003734	Combination Hormone Therapy Followed by Radiation Therapy in Treating Patients With Prostate Cancer	unknown	Phase 3	276	St. Luke's Hospital, IrelandOTHER	2	Jul 21, 2016	clinicaltrials
NCT02749825	Comparison of Trelstar Versus Lupron or Zoladex in Advanced Prostate Cancer	terminated	Phase 4

Molecule

Record

Kind: Other
Mechanism: Gonadotropin-releasing hormone receptor agonist
Targets: 1 gene
Aliases: Arvekap, AY-25650, CL 118,532, CL-118532, DECAPEPTYL, Decapeptyl sr, Gonapeptyl depot, TRELSTAR, Triptodur, TRIPTODUR, Triptorelin, Triptorelina, Triptorelin Acetate, Triptoreline, Triptorelin Pamoate, Tryptorelin, WY-42462

Data updated 2 days agoSource updated unknown

Identifiers

Codes (9)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L02AE04	TRIPTORELIN
DIN (Health Canada)	02240000	TRELSTAR
DIN (Health Canada)	02243856